title: [Effect of dobutamine on ventriculo-arterial coupling and ventricular work efficiency in patients with cardiac failure].
abstract: In nine patients with cardiac dysfunction (ejection fraction less than or equal to 50%), we evaluated the effects of dobutamine (5 micrograms/kg/min) on ventriculo-arterial coupling by monitoring direct arterial pressures and simultaneously-recorded M-mode echocardiograms guided with two-dimensional images. Left ventricular end-diastolic volume (EDV) and end-systolic volume (ESV) were calculated by the formula of Teichholz, and left ventricular end-systolic pressure (ESP) was approximately from the arterial dicrotic pressure. Arterial pressure was altered by phenylephrine or nitroprusside and the slope (Ees) and volume axis intercept (Vo) of the end-systolic pressure-volume relationship were determined as the contractile properties of the ventricle. The arterial system properties were expressed by the slope (Ea) of the end-systolic pressure-stroke volume relationships. Ees during dobutamine infusion was derived assuming that the Vo was unchanged from the baseline state. The left ventricular pressure-volume area (PVA), the sum of external work (EW) and end-systolic potential energy (PE), and ventricular work efficiency (EW/PVA) were determined from a time-varying elastance model. The EDV and ESV were significantly decreased by dobutamine (-4%, p less than 0.05; -22%, p less than 0.01), while the ESP and heart rate remained unchanged. Dobutamine increased the Ees markedly (+41%, p less than 0.01) and decreased the Ea (-23%, p less than 0.01). These changes resulted in a substantial decrease in the ratio of Ea to Ees (-44%, p less than 0.01). The EW was augmented (+22%, p less than 0.01), but the PE was reduced (-33%, p less than 0.01) by dobutamine, while the PVA remained the same as in the baseline state.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Second Department of Internal Medicine, Toyama Medical and Pharmaceutical University.
authors.forename: S
authors.initials: S
authors.lastname: Ishizaka
authors.forename: H
authors.initials: H
authors.lastname: Asanoi
authors.forename: T
authors.initials: T
authors.lastname: Kameyama
authors.forename: S
authors.initials: S
authors.lastname: Sasayama
mesh_terms: D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects*; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy / Q000503:physiopathology*; D004280:Dobutamine / Q000494:pharmacology* / Q000627:therapeutic use; D004452:Echocardiography; D005260:Female; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects*; D013318:Stroke Volume / Q000187:drug effects*; D013599:Systole / Q000187:drug effects*
chemical_list: D004280:Dobutamine